Ascendis Pharma has reported significant findings from the ongoing Phase 2 COACH Trial, demonstrating that the combination therapy of TransCon CNP and TransCon hGH yields unprecedented improvements in arm span and spinal canal dimensions in children with achondroplasia. At Week 52, treatment-naïve participants exhibited a mean change in arm span Z-scores of +1.02, translating to an average increase of 9.4 cm, while those previously treated with TransCon CNP showed a +0.66 Z-score and a 7.9 cm increase. These enhancements are particularly relevant as they extend beyond traditional measures of linear growth, addressing critical aspects of skeletal health.

The clinical implications of these findings suggest a paradigm shift in how treatment outcomes for achondroplasia are evaluated. The combination therapy not only accelerates linear growth but also improves spinal canal dimensions, potentially reducing the risk of nerve compression and associated pain. Specifically, the mean change in interpedicular distance (IPD) for treatment-naïve children was +1.7 mm, compared to only +0.6 mm for those on TransCon CNP monotherapy. Moreover, the tibial femoral angle (TFA) demonstrated enhanced straightening, with a mean change of -3.0 degrees for the combination therapy cohort, indicating a significant improvement in leg alignment.

These results underscore the potential of TransCon CNP and TransCon hGH combination therapy to redefine treatment strategies for achondroplasia, emphasizing a more holistic approach to patient outcomes. As the field progresses, these findings may accelerate the development timelines for therapies targeting skeletal dysplasia, encouraging further exploration of combination treatments that address both growth and associated complications in this patient population.

Source: globenewswire.com